Sort
25,944 grants matching “neurodegeneration”
Mitochondrial and Metabolic Dysfunction in Age-related Neurodegeneration
$2,420,583Gary E Gibson · Winifred Masterson Burke Med Res Inst · P01 · FY2017 · AG
Mitochondrial and Metabolic Dysfunction in Age-related Neurodegeneration
$2,420,583Gary E Gibson · Winifred Masterson Burke Med Res Inst · P01 · FY2020 · AG
Modeling Neurodegenerative Disease Manifestations in Human Enteric Neurons
$2,420,000Faranak Fattahi · University Of California, San Francisco · DP2 · FY2019 · NS
Impact of Amyloid and Tau on the Aging Brain: The Harvard Aging Brain Study
$2,411,664Reisa A. Sperling · Massachusetts General Hospital · P01 · FY2017 · AG
Retinal aging and inherited neurodegenerative diseases
$2,408,833Anand Swaroop · National Eye Institute · ZIA · FY2013 · EY
KBASE2: Korean Brain Aging Study, Longitudinal Endophenotypes and Systems Biology
$2,404,788Andrew J Saykin · Indiana University Indianapolis · U01 · FY2021 · AG
Proteopathies of the Aging Central Nervous System
$2,402,472Lennart Mucke · J. David Gladstone Institutes · P01 · FY2007 · AG
Alzheimer's disease-specific extracellular vesicles: from pathology to novel biomarker discovery
$2,399,582Vasiliki Machairaki · Johns Hopkins University · RF1 · FY2023 · AG
MOLECULAR PATHOGENESIS OF AGE-DEPENDENT CNS DEGENERATION
$2,397,703University Of California San Francisco · P01 · FY2004 · AG
Axonal transport of endolysosomal organelles and presynaptic cargos for the maintenance of axon cellular homeostasis and presynaptic function
$2,397,505Zu-Hang Sheng · National Institute Of Neurological Disorders And Stroke · ZIA · FY2021 · NS
Phase 2 Randomized, Double-Blind, Placebo-Controlled Clinical Trial of T3D-959 in Mild to Moderate Alzheimer's Disease Subjects
$2,396,962John Didsbury · T3d Therapeutics, Inc. · R01 · FY2020 · AG
Frontotemporal Dementias: Genotypes and Phenotypes
$2,394,324Virginia M Lee · University Of Pennsylvania · P01 · FY2016 · AG
Elucidate the roles of Alzheimer's disease risk genes and variants in gene expression and AD-related phenotypes
$2,393,458Yin Shen · University Of California, San Francisco · RF1 · FY2025 · AG
Targeted disruption the enzymes of O-GlcNAc cycling: Animal models of Disease
$2,392,916John A. Hanover · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2023 · DK
Senescent cell mapping, identification and validation for human somatic and reproductive tissues
$2,390,550Birgit Schilling · Buck Institute For Research On Aging · U54 · FY2024 · AG
Chemical Approaches to Understand the Roles of O-GlcNAc Glycosylation in Biology
$2,386,415Linda C Hsieh-Wilson · California Institute Of Technology · RF1 · FY2018 · AG
Stathmin-2 and TDP-43 neurodegeneration in Alzheimerâs and multi-etiology dementias
$2,374,752Keith A Josephs · Mayo Clinic Rochester · RF1 · FY2021 · NS
Genetic and Environmental Risk Factors for Hemorrhagic Stroke â V
$2,374,719Daniel Woo · University Of Cincinnati · RF1 · FY2024 · NS
Dynamic Brain Imaging of Speech in Primary Progressive Aphasia
$2,373,138Srikantan S Nagarajan · University Of California, San Francisco · RF1 · FY2023 · NS
Anti-Viral therapy in Alzheimer's disease
$2,372,211Davangere P Devanand · Columbia University Health Sciences · R01 · FY2019 · AG
Anti-Viral therapy in Alzheimer's disease
$2,372,211Davangere P Devanand · Columbia University Health Sciences · R01 · FY2020 · AG
MOLECULAR PATHOGENESIS OF AGE-DEPENDENT CNS DEGENERATION
$2,372,020University Of California San Francisco · P01 · FY2002 · AG
Validating remote digital assessments for familial frontotemporal dementia
$2,371,437Adam Mark Staffaroni · University Of California, San Francisco · RF1 · FY2022 · AG
Pesticide Use and Markers of ADRD Neurodegeneration among US Farmers
$2,368,557Honglei Chen · Henry Ford Health + Michigan State University Health Sciences · R01 · FY2025 · AG
The BrainCellQTL consortium: QTL mapping in the human brain at the single cell level
$2,367,336Panagiotis Roussos · Icahn School Of Medicine At Mount Sinai · U24 · FY2025 · AG